Tirzepatide vs Semaglutide: Key Differences & Side Effects

Mechanism of Action: GLP-1 vs Dual Agonist (GLP-1+GIP)

There is a fundamental difference between tirzepatide and semaglutide. Tirzepatide is a dual GLP-1 and GIP receptor agonist, whereas semaglutide activates the GLP-1 receptor solely. 

Semaglutide: GLP-1 Receptor Agonist Explained

Semaglutide mimics glucagon-like peptide-1 (GLP-1). It is a long-acting analog of human GLP-1. What does this mean? The medication targets GLP-1 receptors found throughout the gastrointestinal tract, pancreas, and brain. These receptors improve glucose-dependent insulin secretion when blood glucose rises after meals. 

‍

Semaglutide slows how quickly food leaves the stomach and helps the pancreas release more insulin when blood sugar is high. At the same time, it signals the liver to release less sugar (by lowering glucagon). The medication lasts longer in the body because of specific structural changes that help it bind to albumin and resist breakdown by enzymes such as dipeptidyl peptidase-4 (DPP-4).

Tirzepatide: Dual GLP-1 and GIP Receptor Activation

Tirzepatide is a dual GLP-1/GIP receptor co-agonist. This 39-amino acid synthetic peptide acts on both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Studies suggest it engages the GIP receptor more than the GLP-1 receptor in some analyses. Both receptors help regulate insulin release. They appear in brain regions that control food intake.

Evidence from lab and computer studies is mixed (preclinical and early clinical work with investigational tirzepatide). Scientists are still defining how tirzepatide binds to and signals through each receptor, and the clinical impact can vary by patient and dose.

‍

{{primary-cta}}

‍

How These Mechanisms Affect Appetite and Insulin

Tirzepatide’s dual-receptor activation is associated with effects on metabolism and appetite. Research shows that giving GLP-1 and GIP together can increase insulin responses and enhance glucagon suppression compared with either hormone alone. These findings come from studies using investigational tirzepatide (the active ingredient was later marketed under the brand names Mounjaro® and Zepbound®).

Both medications influence appetite by activating GLP-1 receptors in the hypothalamus. This helps alleviate hunger and makes people feel fuller. In a review article, tirzepatide has been shown to reduce energy intake during meals; reported differences between products vary by study design and dose.

Tirzepatide has also been associated with improvements in insulin sensitivity and insulin-secretory responses, including lower prandial insulin and glucagon concentrations in some studies. These findings come from studies using investigational tirzepatide (the active ingredient was later marketed as Mounjaro®  (for type 2 diabetes) and Zepbound® (for obesity).

These metabolic effects may help contextualize clinical weight-loss findings; individual results vary by dose, study population, and adherence.

‍

Weight Loss Outcomes in Clinical Trials

Clinical trials show that these two medications differ in how well they work and the results they achieve.

Semaglutide: 17% Weight Loss Over 68 Weeks

The STEP trials (using Wegovy®) reported clinically meaningful weight loss. Participants lost an average of ~14.9% of their weight over 68 weeks, while the placebo group lost about 2.4%. 

The results were sustained on longer follow-up. Participants maintained an average weight loss of ~15.2% at 104 weeks.

Half of the participants lost at least 15% of their weight, and about a third lost at least 20% of their starting weight.

Tirzepatide: Up to 21% Weight Loss in 72 Weeks

Tirzepatide’s results were higher on average in some trials. The SURMOUNT-1 trial (investigational tirzepatide later marketed as Mounjaro® and Zepbound®) showed that people lost between 15% and 20.9% of their body weight over 72 weeks, depending on their dose. Tirzepatide also produced greater average weight loss than semaglutide in adults with obesity without diabetes. 

So when you compare them directly, head-to-head data showed greater mean weight loss with tirzepatide, and participants were more likely to reach ≥5% and ≥15% weight-loss thresholds than with semaglutide.

Waist Circumference Reduction

Both medications helped people lose inches around their waist, too. People taking semaglutide had a mean reduction of about 14.4 cm at 104 weeks in STEP 5 (using Wegovy®). In SURMOUNT-1 (using investigational tirzepatide), those taking the 15 mg tirzepatide dose reported a mean reduction of ~18.5 cm at 72 weeks.

The data suggest that tirzepatide has a greater average waist reduction at higher doses. But, because the studies used different designs and timeframes, direct comparisons should be interpreted with caution.

Dose-Dependent Results: 5 mg to 15 mg Tirzepatide

In clinical trials, higher tirzepatide doses (with investigational tirzepatide) were associated with greater average weight loss. The 5 mg dose helped people lose 15% of their weight, while 10 mg led to 19.5% loss, and 15 mg resulted in 20.9% loss at 72 weeks.

Higher doses also increased the likelihood of hitting important weight-loss goals. For example, at 15 mg, about 84.3% achieved ≥5% weight loss, while the average loss at that dose was ~20.9% at 72 weeks.

Placebo Comparisons in Both Trials

The placebo groups in both trials showed modest weight changes. People taking a placebo in semaglutide studies lost about 2.4–2.6% of their weight, while those in the tirzepatide trials lost about 3.1%. These results suggest drug effects beyond the lifestyle interventions used across all study arms. However, both programs included structured lifestyle support in placebo and active groups.

‍

{{primary-cta}}

‍

Side Effects and Tolerability Profiles

Both medications cause gastrointestinal (GI) side effects, but they’re different in how often they occur and how severe they are.

Common GI Side Effects: Nausea, Vomiting, Diarrhea

GI problems are the most common side effects of both medications. Reported rates vary by dose, study, and titration schedule. For example, in SURMOUNT-4’s tirzepatide lead-in phase (investigational tirzepatide), nausea occurred in ~35.5%, diarrhea ~21.1%, constipation ~20.7%, and vomiting ~16.3%. The lead-in phase was a 36-week preparatory period before the randomization phase, during which everyone received tirzepatide (no placebo, no blinding) and doses were gradually increased to each person’s best-tolerated level.

For semaglutide 2.4 mg, GI adverse reactions (e.g., nausea, diarrhea, vomiting, constipation) are among the most common events in obesity trials. These side effects usually show up when patients start increasing their doses.

Severity and Duration of Side Effects

Most patients experience mild to moderate side effects that tend to improve over time. In clinical trials, GI symptoms are most common during dose increases and lessen over time. For example, in SURMOUNT-4 (using investigational tirzepatide), nausea occurred in ~35.5% during the 36-week lead-in and ~8.1% during the double-blind period.

Some patients do stop because of GI side effects. The reported discontinuation rates are ~4-8%. It was ~7% during the lead-in in SURMOUNT-4 and 6.8% with semaglutide 2.4 mg in adult Wegovy® trials.

Tirzepatide vs Semaglutide Side Effects: What Studies Show

Some meta-analyses report higher overall GI adverse events with tirzepatide than with semaglutide, but estimates vary by dose and study design. One summary reported that overall GI adverse events were higher with both tirzepatide and semaglutide than with placebo.

Black Box Warning: Thyroid C-Cell Tumors

The FDA requires both medications to carry boxed warnings about thyroid C-cell tumors (based on rodent toxicology studies). The relevance for humans is not yet known. This means patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use these medications.

‍

Dosing, Administration, and Accessibility

The way doctors administer and dose tirzepatide and semaglutide can affect clinical use and tolerability.

Semaglutide Dosing: 0.25 mg to 2.4 mg Weekly

Doctors start semaglutide with a gradual titration at 0.25 mg weekly for the first 4 weeks as an initiation dose. Weight management patients using Wegovy® typically follow a dose increase every 4 weeks to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg for maintenance. Diabetes management with Ozempic® has a lower maximum weekly dose of 1 mg or 2 mg. Both medications come in pre-filled, once-weekly pens. The needle is not exposed during use for subcutaneous injection.

Tirzepatide Dosing: 2.5 mg to 15 mg Weekly

Treatment begins with 2.5 mg tirzepatide weekly for 4 weeks before increasing to 5 mg. Doctors can raise the dose by 2.5 mg every 4 weeks based on how well patients tolerate it and their goals, up to 15 mg weekly. The 2.5 mg dose is for treatment initiation and is not intended for long-term glycemic or weight control. Patients can get the medication in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL.

‍

Brand Names and Indications: Wegovy®, Ozempic®, Mounjaro®, Zepbound®

Doctors prescribe semaglutide under the brand names Ozempic® for diabetes and Wegovy® for weight management. Tirzepatide comes as Mounjaro® for diabetes and Zepbound® for obesity.

The FDA approved Zepbound® for adults with a BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related condition. Patients should not use these medications with other GLP-1 receptor agonists or with other products containing the same active ingredient.

‍

Insurance Coverage and Cost Considerations

Out-of-pocket costs vary widely depending on the pharmacy, dose, and insurance status. Additionally, list prices and programs change over time. The manufacturer may offer savings programs that may lower out-of-pocket costs for eligible patients (program terms vary and change). For Zepbound®, Lilly® has introduced a Zepbound® Self Pay Journey program with transparent monthly prices. Check current pricing on Lilly®-branded materials, as amounts and eligibility may change.

Novo Nordisk® has also publicized a $499/month direct-to-consumer cash option for Wegovy®. Confirm current availability and terms on NovoCare®.

Coverage under Medicare, Medicaid, and other commercial plans differs by state and plan and continues to evolve. Check your current coverage, program criteria, and payer policies for more details.

‍

Switching Between Medications Safely

Patients need medical supervision when switching between these medications, as there isn’t a single, universally accepted protocol. Approaches vary and should be individualized. It is also important to note that product labels advise against using more than one GLP-1 receptor agonist at a time. Patients typically start with lower doses of the new medication, even if they had been taking higher doses before.

‍

Comparison Table

‍

‍

Conclusion

We’ve reviewed key differences between tirzepatide and semaglutide for patients who want to manage their weight. Tirzepatide has shown greater average weight loss in head-to-head clinical trials, with up to a ~21% mean reduction over a 72-week program. Semaglutide achieved ~15-17% in a separate 68-week program. These were separate studies with different designs.

The benefits go beyond just weight loss numbers. Trials also reported decreases in waist circumference (e.g., 18.5 cm with tirzepatide 15 mg at 72 weeks and ~14.4 cm with semaglutide 2.4 mg at 104 weeks). However, it’s important to keep in mind that studies differ in design and timeframe, so direct comparisons should be interpreted with caution.

These improved benefits come with some trade-offs. Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) are common with both medicines, typically during dose escalation. The incidence varies by product, dose, and titration. Some analyses report higher overall GI events with tirzepatide, while others show mixed findings.

Both medications use similar dose increase patterns and come with similar warnings about thyroid tumors. Out-of-pocket costs vary by dose, pharmacy, and coverage. Manufacturers may offer savings programs for eligible patients, and the terms change over time.

The best choice between these medications depends on your goals, medical history, and how well you handle side effects. Discuss with your clinician which option aligns with your goals and tolerability. Both medications are important advances in weight management that can help people living with obesity and related health issues. A conversation with your healthcare provider will help determine which option works best for your health needs and situation.

‍

‍